Roger Paredes, MD, PhD, is Head of the Department of Infectious Diseases at the Hospital Germans Trias i Pujol and Principal Investigator of the Microbial Genomics Group at the IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain. He obtained his MD, PhD degree in Medicine and Surgery from the Autonomous University of Barcelona (UAB) and specialised in HIV research at the Brigham & Women’s Hospital, Harvard Medical School, supported by a "la Caixa" grant for postgraduate studies. His team at irsiCaixa determined the clinical utility of HIV-1 deep sequencing in both high- and low-income countries. Currently, his team leads pioneering research into the role of the gut microbiome in the pathogenesis of HIV infection and chronic inflammation. He coordinates the Horizon 2020 MISTRAL project (# 847943) and is co-PI in three projects of microbiome in HIV, HPV and cancer funded by the Canadian Institutes for Health Research. Since the COVID-19 pandemic outbreak, Dr Paredes has been the Spanish National Coordinator of several NIH/NIAID-funded randomized clinical trials, including ACTT-1 and 2 and the ACTIV-3/TICO and STRIVE platforms, and has coauthored seminal publications on the role of different SARS-CoV-2 antivirals in preventing severe COVID-19 in high-risk populations. Such studies have defined the current standard of care of COVID-19 in hospitalized patients as well as in outpatients. His department hosts the largest Long COVID Unit in Spain.
Spain